Please assess the completion status of the following clinical trial:

Trial Title: Safety of Estrogens in Lupus: Birth Control Pills

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female~* Unequivocal diagnosis of SLE~* Inactive disease or be stable on 0.5 mg/kg/day or less of predisone~* Must be between 18 and 39 years old if non-smoker~* Must be between 18 and 35 years old if smoker~Exclusion Criteria:~* Blood pressure \>145/95 on three occasions~* Deep vein, arterial thrombosis or pulmonary embolus~* GPL \>40; MPL \>40; APL \>50; dRVVT \>37 sec~* APL antibody syndrome ever~* Gynecologic or breast cancer~* Hepatic dysfunction or liver tumors~* Diabetes mellitus (NOT due to steroids) with vascular disease~* Congenital hyperlipidemia~* Complicated migraine~* Severe disease activity (SLEDAI \>12)~* Increase in SLEDAI \>2 points in 3 months~* Unexplained vaginal bleeding~* Use of estrogen (OCP) for \>1 month at any time after SLE diagnosis~* Present pregnancy~* Angina or MI due to APS~* Age \>35 yrs. for smokers; \>39 yrs. for nonsmokers

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).